217 related articles for article (PubMed ID: 22076249)
1. Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.
Schlossarek S; Schuermann F; Geertz B; Mearini G; Eschenhagen T; Carrier L
J Muscle Res Cell Motil; 2012 May; 33(1):5-15. PubMed ID: 22076249
[TBL] [Abstract][Full Text] [Related]
2. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T
J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226
[TBL] [Abstract][Full Text] [Related]
3. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice.
Fraysse B; Weinberger F; Bardswell SC; Cuello F; Vignier N; Geertz B; Starbatty J; Krämer E; Coirault C; Eschenhagen T; Kentish JC; Avkiran M; Carrier L
J Mol Cell Cardiol; 2012 Jun; 52(6):1299-307. PubMed ID: 22465693
[TBL] [Abstract][Full Text] [Related]
4. Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice.
Barefield D; Kumar M; Gorham J; Seidman JG; Seidman CE; de Tombe PP; Sadayappan S
J Mol Cell Cardiol; 2015 Feb; 79():234-43. PubMed ID: 25463273
[TBL] [Abstract][Full Text] [Related]
5. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
[TBL] [Abstract][Full Text] [Related]
6. Selective phosphorylation of PKA targets after β-adrenergic receptor stimulation impairs myofilament function in Mybpc3-targeted HCM mouse model.
Najafi A; Sequeira V; Helmes M; Bollen IA; Goebel M; Regan JA; Carrier L; Kuster DW; Van Der Velden J
Cardiovasc Res; 2016 May; 110(2):200-14. PubMed ID: 26825555
[TBL] [Abstract][Full Text] [Related]
7. Translational investigation of electrophysiology in hypertrophic cardiomyopathy.
Flenner F; Jungen C; Küpker N; Ibel A; Kruse M; Koivumäki JT; Rinas A; Zech ATL; Rhoden A; Wijnker PJM; Lemoine MD; Steenpass A; Girdauskas E; Eschenhagen T; Meyer C; van der Velden J; Patten-Hamel M; Christ T; Carrier L
J Mol Cell Cardiol; 2021 Aug; 157():77-89. PubMed ID: 33957110
[TBL] [Abstract][Full Text] [Related]
8. Characterization of heterozygous and homozygous mouse models with the most common hypertrophic cardiomyopathy mutation MYBPC3
Hilderink S; Schuldt M; Goebel M; Jansen VJ; Manders E; Moorman S; Dorsch LM; van Steenbeek FG; van der Velden J; Kuster DWD
J Mol Cell Cardiol; 2023 Dec; 185():65-76. PubMed ID: 37844837
[TBL] [Abstract][Full Text] [Related]
9. Sexual dimorphic response to exercise in hypertrophic cardiomyopathy-associated MYBPC3-targeted knock-in mice.
Najafi A; Schlossarek S; van Deel ED; van den Heuvel N; Güçlü A; Goebel M; Kuster DW; Carrier L; van der Velden J
Pflugers Arch; 2015 Jun; 467(6):1303-17. PubMed ID: 25010737
[TBL] [Abstract][Full Text] [Related]
10. AT1 blockade abolishes left ventricular hypertrophy in heterozygous cMyBP-C null mice: role of FHL1.
Vignier N; Le Corvoisier P; Blard C; Sambin L; Azibani F; Schlossarek S; Delcayre C; Carrier L; Hittinger L; Su JB
Fundam Clin Pharmacol; 2014 Jun; 28(3):249-56. PubMed ID: 23600722
[TBL] [Abstract][Full Text] [Related]
11. Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy.
Schlossarek S; Englmann DR; Sultan KR; Sauer M; Eschenhagen T; Carrier L
Basic Res Cardiol; 2012 Jan; 107(1):235. PubMed ID: 22189562
[TBL] [Abstract][Full Text] [Related]
12. The embryological basis of subclinical hypertrophic cardiomyopathy.
Captur G; Ho CY; Schlossarek S; Kerwin J; Mirabel M; Wilson R; Rosmini S; Obianyo C; Reant P; Bassett P; Cook AC; Lindsay S; McKenna WJ; Mills K; Elliott PM; Mohun TJ; Carrier L; Moon JC
Sci Rep; 2016 Jun; 6():27714. PubMed ID: 27323879
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.
Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L
J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529
[TBL] [Abstract][Full Text] [Related]
14. Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy.
Barefield D; Kumar M; de Tombe PP; Sadayappan S
Am J Physiol Heart Circ Physiol; 2014 Mar; 306(6):H807-15. PubMed ID: 24464755
[TBL] [Abstract][Full Text] [Related]
15. The Metabolome in Finnish Carriers of the MYBPC3-Q1061X Mutation for Hypertrophic Cardiomyopathy.
Jørgenrud B; Jalanko M; Heliö T; Jääskeläinen P; Laine M; Hilvo M; Nieminen MS; Laakso M; Hyötyläinen T; Orešič M; Kuusisto J
PLoS One; 2015; 10(8):e0134184. PubMed ID: 26267065
[TBL] [Abstract][Full Text] [Related]
16. Activation of Autophagy Ameliorates Cardiomyopathy in
Singh SR; Zech ATL; Geertz B; Reischmann-Düsener S; Osinska H; Prondzynski M; Krämer E; Meng Q; Redwood C; van der Velden J; Robbins J; Schlossarek S; Carrier L
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29021349
[TBL] [Abstract][Full Text] [Related]
17. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes.
Poutanen T; Tikanoja T; Jääskeläinen P; Jokinen E; Silvast A; Laakso M; Kuusisto J
Am Heart J; 2006 Mar; 151(3):725.e1-725.e9. PubMed ID: 16504640
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
[TBL] [Abstract][Full Text] [Related]
19. Hypertrophic cardiomyopathy in myosin-binding protein C (
Adalsteinsdottir B; Burke M; Maron BJ; Danielsen R; Lopez B; Diez J; Jarolim P; Seidman J; Seidman CE; Ho CY; Gunnarsson GT
Open Heart; 2020; 7(1):e001220. PubMed ID: 32341788
[TBL] [Abstract][Full Text] [Related]
20. Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathy.
Mori AA; Castro LR; Bortolin RH; Bastos GM; Oliveira VF; Ferreira GM; Hirata TDC; Fajardo CM; Sampaio MF; Moreira DAR; Pachón-Mateos JC; Correia EB; Sousa AGMR; Brión M; Carracedo A; Hirata RDC; Hirata MH
Forensic Sci Int Genet; 2021 May; 52():102478. PubMed ID: 33588347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
